<!DOCTYPE html>
<html lang="en"><head>
<script src="Lecture1_files/libs/clipboard/clipboard.min.js"></script>
<script src="Lecture1_files/libs/quarto-html/tabby.min.js"></script>
<script src="Lecture1_files/libs/quarto-html/popper.min.js"></script>
<script src="Lecture1_files/libs/quarto-html/tippy.umd.min.js"></script>
<link href="Lecture1_files/libs/quarto-html/tippy.css" rel="stylesheet">
<link href="Lecture1_files/libs/quarto-html/light-border.css" rel="stylesheet">
<link href="Lecture1_files/libs/quarto-html/quarto-syntax-highlighting-e1a5c8363afafaef2c763b6775fbf3ca.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<link href="Lecture1_files/libs/quarto-contrib/fontawesome6-0.1.0/all.css" rel="stylesheet">
<link href="Lecture1_files/libs/quarto-contrib/fontawesome6-0.1.0/latex-fontsize.css" rel="stylesheet">
<script src="Lecture1_files/libs/quarto-contrib/glightbox/glightbox.min.js"></script>
<link href="Lecture1_files/libs/quarto-contrib/glightbox/glightbox.min.css" rel="stylesheet">
<link href="Lecture1_files/libs/quarto-contrib/glightbox/lightbox.css" rel="stylesheet"><meta charset="utf-8">
  <meta name="generator" content="quarto-1.7.31">

  <title>lecture1</title>
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black-translucent">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no, minimal-ui">
  <link rel="stylesheet" href="Lecture1_files/libs/revealjs/dist/reset.css">
  <link rel="stylesheet" href="Lecture1_files/libs/revealjs/dist/reveal.css">
  <style>
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    div.columns{display: flex; gap: min(4vw, 1.5em);}
    div.column{flex: auto; overflow-x: auto;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    ul.task-list{list-style: none;}
    ul.task-list li input[type="checkbox"] {
      width: 0.8em;
      margin: 0 0.8em 0.2em -1em; /* quarto-specific, see https://github.com/quarto-dev/quarto-cli/issues/4556 */ 
      vertical-align: middle;
    }
    /* CSS for citations */
    div.csl-bib-body { }
    div.csl-entry {
      clear: both;
      margin-bottom: 0em;
    }
    .hanging-indent div.csl-entry {
      margin-left:2em;
      text-indent:-2em;
    }
    div.csl-left-margin {
      min-width:2em;
      float:left;
    }
    div.csl-right-inline {
      margin-left:2em;
      padding-left:1em;
    }
    div.csl-indent {
      margin-left: 2em;
    }  </style>
  <link rel="stylesheet" href="Lecture1_files/libs/revealjs/dist/theme/quarto-1ba128c3b957e260fc11512a5c026fdd.css">
  <link href="Lecture1_files/libs/revealjs/plugin/quarto-line-highlight/line-highlight.css" rel="stylesheet">
  <link href="Lecture1_files/libs/revealjs/plugin/reveal-menu/menu.css" rel="stylesheet">
  <link href="Lecture1_files/libs/revealjs/plugin/reveal-menu/quarto-menu.css" rel="stylesheet">
  <link href="Lecture1_files/libs/revealjs/plugin/reveal-chalkboard/font-awesome/css/all.css" rel="stylesheet">
  <link href="Lecture1_files/libs/revealjs/plugin/reveal-chalkboard/style.css" rel="stylesheet">
  <link href="Lecture1_files/libs/revealjs/plugin/quarto-support/footer.css" rel="stylesheet">
  <style type="text/css">
    .reveal div.sourceCode {
      margin: 0;
      overflow: auto;
    }
    .reveal div.hanging-indent {
      margin-left: 1em;
      text-indent: -1em;
    }
    .reveal .slide:not(.center) {
      height: 100%;
      overflow-y: auto;
    }
    .reveal .slide.scrollable {
      overflow-y: auto;
    }
    .reveal .footnotes {
      height: 100%;
      overflow-y: auto;
    }
    .reveal .slide .absolute {
      position: absolute;
      display: block;
    }
    .reveal .footnotes ol {
      counter-reset: ol;
      list-style-type: none; 
      margin-left: 0;
    }
    .reveal .footnotes ol li:before {
      counter-increment: ol;
      content: counter(ol) ". "; 
    }
    .reveal .footnotes ol li > p:first-child {
      display: inline-block;
    }
    .reveal .slide ul,
    .reveal .slide ol {
      margin-bottom: 0.5em;
    }
    .reveal .slide ul li,
    .reveal .slide ol li {
      margin-top: 0.4em;
      margin-bottom: 0.2em;
    }
    .reveal .slide ul[role="tablist"] li {
      margin-bottom: 0;
    }
    .reveal .slide ul li > *:first-child,
    .reveal .slide ol li > *:first-child {
      margin-block-start: 0;
    }
    .reveal .slide ul li > *:last-child,
    .reveal .slide ol li > *:last-child {
      margin-block-end: 0;
    }
    .reveal .slide .columns:nth-child(3) {
      margin-block-start: 0.8em;
    }
    .reveal blockquote {
      box-shadow: none;
    }
    .reveal .tippy-content>* {
      margin-top: 0.2em;
      margin-bottom: 0.7em;
    }
    .reveal .tippy-content>*:last-child {
      margin-bottom: 0.2em;
    }
    .reveal .slide > img.stretch.quarto-figure-center,
    .reveal .slide > img.r-stretch.quarto-figure-center {
      display: block;
      margin-left: auto;
      margin-right: auto; 
    }
    .reveal .slide > img.stretch.quarto-figure-left,
    .reveal .slide > img.r-stretch.quarto-figure-left  {
      display: block;
      margin-left: 0;
      margin-right: auto; 
    }
    .reveal .slide > img.stretch.quarto-figure-right,
    .reveal .slide > img.r-stretch.quarto-figure-right  {
      display: block;
      margin-left: auto;
      margin-right: 0; 
    }
  </style>
</head>
<body class="quarto-light">
  <div class="reveal">
    <div class="slides">


<section id="lecture-5-cephalosporins-and-carbapenems" class="slide level2" data-background-video="login-lores.mp4" data-background-video-loop="true" data-background-opacity="0.3">
<h2>Lecture 5: Cephalosporins and carbapenems</h2>
<p><br> <br> <br> <br></p>
<p><strong>Russell E. Lewis</strong> <br> Associate Professor of Infectious Diseases <br> Department of Molecular Medicine <br> University of Padua</p>
<p><br> <i class="fa-solid fa-envelope fa-1x" aria-label="envelope"></i> russelledward.lewis@unipd.it <br> <i class="fa-brands fa-github fa-1x" aria-label="github"></i> <a href="https://github.com/Russlewisbo/ESCMID_2022_talk">https://github.com/Russlewisbo</a></p>
<p><a href="images/University_of_Padua_seal.svg" class="lightbox" data-gallery="quarto-lightbox-gallery-1"><img data-src="images/University_of_Padua_seal.svg" width="100"></a></p>
</section>
<section id="agenda" class="slide level2">
<h2>Agenda</h2>
</section>
<section id="discovery-of-cephalosporins" class="slide level2 smaller">
<h2>Discovery of cephalosporins</h2>
<p><br></p>
<div class="columns">
<div class="column" style="width:40%;">
<p><a href="images/Bronzu.png" class="lightbox" data-gallery="quarto-lightbox-gallery-2"><img data-src="images/Bronzu.png" width="800"></a></p>
</div><div class="column" style="width:60%;">
<p><br></p>
<ul>
<li>Bronzu performed epidemiological studies of typhoid infection in Cagliari, noted <em>Salmonella typhi</em> was not cultured once sewer water was discharged into the sea</li>
<li>Isolated the mold <em>Cephalosporium</em> (now known as <em>Acremonium</em>) in 1948 from seawater</li>
<li>Noticed that these cultures produced substances (he named mycetin) that were effective against <em>Salmonella typhi</em>, the cause of typhoid fever, which had beta-lactamase.</li>
<li>After he failed to find support from Italian government, he sent the fungus to Howard Florey at Oxford</li>
<li>1962: Isolation of cephalosporin C</li>
</ul>
</div></div>
</section>
<section id="mechanism-of-action-of-cephalosporins-similar-to-β-lactams" class="slide level2">
<h2>Mechanism of action of cephalosporins: <br> Similar to β-lactams</h2>
<p><br></p>
<div class="columns">
<div class="column" style="width:50%;">
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="https://i.makeagif.com/media/4-07-2017/l7_PRO.gif" class="lightbox" data-gallery="quarto-lightbox-gallery-3" title="Inhibition of transpeptidase (PBP)"><img data-src="https://i.makeagif.com/media/4-07-2017/l7_PRO.gif" alt="Inhibition of transpeptidase (PBP)"></a></p>
<figcaption>Inhibition of transpeptidase (PBP)</figcaption>
</figure>
</div>
</div><div class="column" style="width:50%;">
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="https://i.makeagif.com/media/10-05-2017/e3c7kf.gif" class="lightbox" data-gallery="quarto-lightbox-gallery-4" title="Lysis of growing bacterial cells"><img data-src="https://i.makeagif.com/media/10-05-2017/e3c7kf.gif" alt="Lysis of growing bacterial cells"></a></p>
<figcaption>Lysis of growing bacterial cells</figcaption>
</figure>
</div>
</div></div>
<p><br></p>
</section>
<section id="first-generation-cephalosporins-derivatives-of-7-aca" class="slide level2 smaller">
<h2>First generation cephalosporins; <br> derivatives of 7-ACA</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/1gen.png" class="lightbox" data-gallery="quarto-lightbox-gallery-5"><img data-src="images/1gen.png" class="quarto-figure quarto-figure-center" width="400"></a></p>
</figure>
</div>

<aside><div>
<ul>
<li>Gram positive activity: Cover Methicillin-sensitive <em>S. aureus</em> (MSSA) and streptococci:</li>
<li>Used for uncomplicated skin and soft-tissue infections (SSI)</li>
<li>Surgical prophylaxis: cefazolin</li>
<li>Some gram-negative coverage in urine: Non-ESBL producing <em>P. mirabilis, E. coli, and K. pneumoniae</em></li>
</ul>
</div></aside></section>
<section id="pharmacokinetics-1st-generation-cephalosporins" class="slide level2 smaller">
<h2>Pharmacokinetics: 1st generation cephalosporins</h2>
<p><br> <br></p>
<table class="caption-top">
<colgroup>
<col style="width: 22%">
<col style="width: 77%">
</colgroup>
<tbody>
<tr class="odd">
<td><strong>Absorption</strong></td>
<td>Cefadroxil (90%); cephalexin (90%); cefazolin (IV only)</td>
</tr>
<tr class="even">
<td><strong>Distribution</strong></td>
<td><ul>
<li><p>0.19-0.35 L/kg</p></li>
<li><p>Protein binding: 20% cefadroxil, cephalexin; 73-87% cefazolin</p></li>
<li><p>25% bile:serum; cefazolin:29-300%</p></li>
<li><p>5-10% CSF:blood (possibly for cefazolin with higher doses)</p></li>
</ul></td>
</tr>
<tr class="odd">
<td><strong>Metabolism</strong></td>
<td><ul>
<li><p>No metabolism</p></li>
<li><p>t½: Cefazolin (2 hrs); cefadroxil (1.5 hrs); cephalexin (1hr)</p></li>
</ul></td>
</tr>
<tr class="even">
<td><strong>Elimination</strong></td>
<td>Renal 100%, impaired by probenicid</td>
</tr>
<tr class="odd">
<td><strong>PK:PD target</strong></td>
<td>≥ 40-50% <em>f</em>Time<sub>&gt;MIC</sub></td>
</tr>
<tr class="even">
<td><strong>Typical doses</strong></td>
<td><p>Cefazolin: 1-2 gram IV every 8 hours</p>
<p>Cefadroxil: 500-1000 mg BID</p>
<p>Cephalexin 250-1000 mg QID</p></td>
</tr>
</tbody>
</table>
</section>
<section id="avoid-cefazolin-for-cns-infections" class="slide level2">
<h2>Avoid cefazolin for CNS infections?</h2>
<p><br></p>
<div class="columns">
<div class="column" style="width:50%;">
<p><a href="images/myth1.png" class="lightbox" data-gallery="quarto-lightbox-gallery-6"><img data-src="images/myth1.png"></a></p>
</div><div class="column" style="width:50%;">
<p><a href="images/myth2.png" class="lightbox" data-gallery="quarto-lightbox-gallery-7"><img data-src="images/myth2.png"></a></p>
</div></div>

<aside><div>
<p><span class="citation" data-cites="mccreary.etal_2023b">(<a href="#/references" role="doc-biblioref" onclick="">McCreary et al., 2023</a>)</span></p>
</div></aside></section>
<section id="why-this-myth-has-been-busted" class="slide level2">
<h2>Why this myth has been busted?</h2>
<p><br></p>
<ul>
<li><strong>Earlier recommendations based on breakthrough reports with cephalothin and single point samples suggesting low CSF concentrations</strong></li>
<li><strong>More recent data have documented attainment of therapeutic exposures with higher dose regimens:</strong>
<ul>
<li>A recent narrative review on the treatment of cefazolin for CNS infections (including 11 reports describing cefazolin treatment of spinal epidural abscesses in a total of 104 patients) recommends <span style="border-radius: 0.2rem; padding: 0 0.2rem 0 0.2rem;background-color: #ffe536;">2 g IV every 6 hours or a continuous infusion of 8–10 g daily</span> instead of the traditional 1–2 g IV every 8 hours dosing scheme to optimize pharmacokinetic/pharmacodynamic properties</li>
</ul></li>
</ul>

<aside><div>
<p><span class="citation" data-cites="antosz.etal_2023a">(<a href="#/references" role="doc-biblioref" onclick="">Antosz et al., 2023</a>)</span></p>
</div></aside></section>
<section id="another-cefazolin-myth-busted-penicillin-cross-allergy" class="slide level2 smaller">
<h2>Another cefazolin myth busted? <br> penicillin cross-allergy</h2>
<p><br></p>
<div class="columns">
<div class="column" style="width:50%;">
<p><a href="images/myth3.png" class="lightbox" data-gallery="quarto-lightbox-gallery-8"><img data-src="images/myth3.png" width="500"></a></p>
</div><div class="column" style="width:50%;">
<p><a href="images/myth4.png" class="lightbox" data-gallery="quarto-lightbox-gallery-9"><img data-src="images/myth4.png" width="600"></a></p>
</div></div>

<aside><div>
<p><span class="citation" data-cites="mccreary.etal_2023b">(<a href="#/references" role="doc-biblioref" onclick="">McCreary et al., 2023</a>)</span></p>
</div></aside></section>
<section id="second-generation-cephalosporins" class="slide level2 smaller">
<h2>Second generation cephalosporins</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/2ndgen.png" class="lightbox" data-gallery="quarto-lightbox-gallery-10"><img data-src="images/2ndgen.png" class="quarto-figure quarto-figure-center" width="600"></a></p>
</figure>
</div>
</section>
<section id="spectrum-of-activity" class="slide level2 smaller">
<h2>Spectrum of activity</h2>
<p><br></p>
<ul>
<li><p><strong>Enhanced Gram-negative coverage:</strong> Effective against a variety of Gram-negative bacilli, including Haemophilus influenzae, Enterobacter aerogenes, Neisseria species, and some Escherichia coli and Klebsiella species.</p></li>
<li><p><strong>Gram-positive activity:</strong> Retain good activity against many Gram-positive cocci, such as Streptococcus pneumoniae and Streptococcus pyogenes, but generally less active than first-generation cephalosporins against Staphylococcus aureus.</p></li>
<li><p><strong>Anaerobic bacteria:</strong> Some second-generation cephalosporins, like cefoxitin and cefotetan, have activity against anaerobic bacteria, including Bacteroides fragilis, which makes them useful for abdominal infections.</p></li>
<li><p><strong>Limited against beta-lactamase producers:</strong> While they have improved resistance to beta-lactamases compared to first-generation cephalosporins, many second-generation cephalosporins are still susceptible to beta-lactamase enzymes produced by certain bacteria, limiting their effectiveness against these resistant strains.</p></li>
</ul>
</section>
<section id="pharmacokinetics-of-representative-2nd-generation-cephalosporins" class="slide level2 smaller">
<h2>Pharmacokinetics of representative 2nd generation cephalosporins</h2>
<p><br> <br></p>
<table class="caption-top">
<colgroup>
<col style="width: 21%">
<col style="width: 78%">
</colgroup>
<tbody>
<tr class="odd">
<td><strong>Absorption</strong></td>
<td>Cefuroxime (52%), cefprozil (95%), cefaclor (93%)</td>
</tr>
<tr class="even">
<td><strong>Distribution</strong></td>
<td><ul>
<li><p>0.15-0.35 L/kg</p></li>
<li><p>Protein binding: 36-50%</p></li>
<li><p>25% bile:serum; cefazolin:29-300%</p></li>
<li><p>5-10% CSF:blood (possibly for cefazolin with higher doses)</p></li>
</ul></td>
</tr>
<tr class="odd">
<td><strong>Metabolism</strong></td>
<td><ul>
<li><p>No metabolism</p></li>
<li><p>t½: cefuroxime (1.5hrs); cefadroxil (1.5 hrs); cefotetan( 3-4 hr) |</p></li>
</ul></td>
</tr>
<tr class="even">
<td><strong>Elimination</strong></td>
<td>Renal 100%</td>
</tr>
<tr class="odd">
<td><strong>PK:PD target</strong></td>
<td>≥ 40-50% <em>f</em>Time<sub>&gt;MIC</sub></td>
</tr>
<tr class="even">
<td><strong>Typical doses</strong></td>
<td><p>cefaclor: 250-500 mg TID</p>
<p>cefuroxime: 250-500 BID</p>
<p>cefotetan: 1-2 gram IV q12h</p></td>
</tr>
</tbody>
</table>

<aside><div>
<p>Source: Sanford Guide</p>
</div></aside></section>
<section id="nd-generation-cephalosporins-what-is-their-role" class="slide level2">
<h2>2nd generation cephalosporins: <br> What is their role?</h2>
<p><br></p>
<ul>
<li><p>Cefotetan- GI surgical prophylaxis (resistance is increasing in <em>B. fragilis</em>)</p></li>
<li><p>Upper respiratory tract infections, CAP, gonorrhea,…</p>
<ul>
<li>but these are “in between” antibiotics and often passed over for better options</li>
</ul></li>
</ul>
</section>
<section id="rd-generation-cephalosporins" class="slide level2 smaller">
<h2>3rd generation cephalosporins</h2>
<p><br></p>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/3rdgen.png" class="lightbox" data-gallery="quarto-lightbox-gallery-11"><img data-src="images/3rdgen.png" class="quarto-figure quarto-figure-center" width="400"></a></p>
</figure>
</div>
</section>
<section id="rd-generation-cephalosporins-spectrum" class="slide level2 smaller">
<h2>3rd generation cephalosporins: spectrum</h2>
<h3 id="gram-positive-coverage">Gram-Positive Coverage</h3>
<ul>
<li><p><strong>Reduced compared to 1st/2nd generation</strong> cephalosporins</p></li>
<li><p>Moderate activity against <strong>Streptococcus pneumoniae</strong> and other streptococci</p></li>
<li><p><strong>Poor activity</strong> against methicillin-resistant Staphylococcus aureus (MRSA)</p></li>
<li><p>Limited activity against <strong>Enterococcus species</strong></p></li>
<li><p>Ceftriaxone maintains reasonable activity against penicillin-susceptible S. pneumoniae</p></li>
</ul>
<h3 id="gram-negative-coverage-primary-role">Gram-Negative Coverage (Primary role)</h3>
<ul>
<li><p><strong>Excellent activity</strong> against Enterobacteriaceae:</p>
<ul>
<li><p><em>E. coli</em></p></li>
<li><p><em>Klebsiella species</em></p></li>
<li><p><em>Proteus mirabilis</em></p></li>
<li><p><em>Citrobacter species</em></p></li>
<li><p><em>Serratia marcescens</em></p></li>
</ul></li>
<li><p>Good activity against <strong>Haemophilus influenzae</strong> (including β-lactamase producers)</p></li>
<li><p>Coverage of <strong><em>Neisseria gonorrhoeae</em></strong> and <strong><em>N. meningitidis</em></strong></p></li>
<li><p><strong>Ceftazidime</strong> uniquely covers <strong><em>Pseudomonas aeruginosa</em></strong></p></li>
<li><p>Generally active against <strong><em>Moraxella catarrhalis</em></strong></p></li>
</ul>
</section>
<section id="notable-gaps-3rd-generation-cephalosporins" class="slide level2 smaller">
<h2>Notable Gaps: <br> 3rd generation cephalosporins</h2>
<h3 id="no-activity-against">No activity against:</h3>
<ul>
<li><p>MRSA or methicillin-resistant coagulase-negative staphylococci</p></li>
<li><p>Enterococcus faecalis/faecium</p></li>
<li><p>Listeria monocytogenes</p></li>
<li><p>Atypical pathogens (Mycoplasma, Chlamydia, Legionella)</p></li>
<li><p>Most anaerobes (except some activity from ceftriaxone/cefotaxime)</p></li>
<li><p>Extended-spectrum β-lactamase (ESBL) producing organisms</p></li>
<li><p>AmpC β-lactamase producers</p></li>
</ul>
<h3 id="key-clinical-agents">Key Clinical Agents</h3>
<ul>
<li><p><strong>Ceftriaxone/Cefotaxime</strong>: Broader spectrum, CNS penetration</p></li>
<li><p><strong>Ceftazidime</strong>: Anti-pseudomonal activity</p></li>
<li><p><strong>Cefixime</strong>: Oral option with good gram-negative coverage (non-ESBL)</p></li>
<li><p><strong>Ceftibuten/Cefdinir</strong>: Other oral options with varying spectra</p></li>
</ul>
</section>
<section id="pharmacokinetics-3rd-generation-cephalosporins" class="slide level2 smaller">
<h2>Pharmacokinetics: <br>3rd generation cephalosporins</h2>
<table class="caption-top" style="width:100%;">
<colgroup>
<col style="width: 9%">
<col style="width: 86%">
<col style="width: 4%">
</colgroup>
<tbody>
<tr class="odd">
<td><strong>Absorption</strong></td>
<td>Cefpodoxime (56%); Cefexime (50%); Cefoperazone (IV); Ceftazidime (IV); Cefotaxime (IV); Ceftriaxone (IV, IM)</td>
<td></td>
</tr>
<tr class="even">
<td><strong>Distribution</strong></td>
<td><ul>
<li><p>0.15-0.93 L/kg</p></li>
<li><p>Protein binding: &lt;10% ceftazidime; 30-70% cefotaxime, cefpodoxime, cefixime; &gt; 85-90% cefoperazone, ceftriaxone</p></li>
<li><p>CSF/Blood &gt; 10%: cefotaxime, ceftazidime; ceftriaxone,</p></li>
</ul></td>
<td></td>
</tr>
<tr class="odd">
<td><strong>Metabolism</strong></td>
<td><ul>
<li><p>No metabolism</p></li>
<li><p>t½: cefotaxime, ceftazidime, cefoperazone; 1.5-2 hr; cefpodoxime 2.5 hr; cefixime 3hr; ceftriaxone 8 hr;</p></li>
</ul></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Elimination</strong></td>
<td>All renal except: ceftriaxone and cefoperazone undergo primarily biliary elimination</td>
<td></td>
</tr>
<tr class="odd">
<td><strong>PK:PD target</strong></td>
<td>≥ 40-50% <em>f</em>Time<sub>&gt;MIC</sub></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Typical doses</strong></td>
<td>Cefotaxime 2 grams IV q8h; cefpodoxime 200-400 mg BID; ceftazidime 1-2 gram IV q8h or 15 mg/kg LD then 6 G IV over 24h; ceftriaxone 1-2 grams IV 24h (q12h meningitis); cefixime 400 mg BID</td>
<td></td>
</tr>
</tbody>
</table>
</section>
<section id="rd-generation-cephalosporins-role-in-treatment" class="slide level2">
<h2>3rd Generation Cephalosporins: <br> Role in treatment</h2>
<p><br></p>
<ul>
<li>Extended gram-negative bacteria coverage, often used to treat gram-negative infections resistant to the first- and second-generation or other β-lactam antimicrobials</li>
<li>Ceftriaxone and cefotaxime penetrate the blood-brain barrier and cover bacteria in the cerebral spinal fluid
<ul>
<li>Ceftriaxone can be prescribed&nbsp;to treat meningitis caused by <em>Haemopohilus influenzae</em>,&nbsp;<em>Neisseria meningitidis</em>, or&nbsp;<em>Streptococcus pneumoniae</em></li>
<li>Ceftriaxone is also used to treat gonorrhea and disseminated Lyme disease</li>
<li>Ceftazidime has <em>Pseudomonas aeruginosa</em> coverage</li>
</ul></li>
</ul>
</section>
<section id="key-issues-with-ceftriaxone-dosing" class="slide level2 small">
<h2>Key issues with ceftriaxone dosing</h2>
<p><br></p>
<ul>
<li>Often avoided in neonates, because of displacement of bilirubin (cefotaxime used instead)</li>
<li>2 gram q24h dose has largely replaced 1 gram dose for most indications (similar safety, improved PK/PD target in obese/ critically ill)
<ul>
<li>Risk for low exposure: low albumin, augmented renal clearance, sepsis</li>
<li>High protein binding a key component that slows ceftriaxone clearance</li>
</ul></li>
<li>Meningitis dose: 2 gram IV q12h</li>
</ul>
</section>
<section id="higher-failure-rates-of-2nd-and-3rd-generation-cephalosporins-for-mssa" class="slide level2 small">
<h2>Higher failure rates of 2nd and <br> 3rd generation cephalosporins for MSSA?</h2>
<ul>
<li>MSSA MIC breakpoints historically have been too high (MIC ≤ 8) vs.&nbsp;gram negatives (MIC ≤ 1, set to address ESBL test problems)
<ul>
<li>Oxacillin and cefoxitin susceptibility are probably not a good predictor of ceftriaxone susceptibility among MSSA</li>
</ul></li>
<li>In vitro, killing by ceftriaxone (esp.&nbsp;in presence of albumin) is much slower versus anti-staphylococcal PCNs</li>
<li>Yet, observational clinical studies provide conflicting evidence whether ceftriaxone is inferior</li>
<li>In clinical PK/PD analysis, ceftriaxone 2 grams daily had a clinical failure rate of 55%, which was almost the same as vancomycin 1 gram Q12
<ul>
<li>Ceftriaxone 2 gram q12 needed to give the best chance of covering MSSA</li>
<li>OPAT convenience: cefazolin 2 gram q12h or daptomycin 6-8 mg/kg once daily</li>
</ul></li>
</ul>

<aside><div>
<p><span class="citation" data-cites="paul.etal_2011 zelenitsky.etal_2018">(<a href="#/references" role="doc-biblioref" onclick="">Paul et al., 2011</a>; <a href="#/references" role="doc-biblioref" onclick="">Zelenitsky et al., 2018</a>)</span></p>
</div></aside></section>
<section id="ceftriaxone-for-enterococcal-endocarditis" class="slide level2 smaller">
<h2>Ceftriaxone for enterococcal endocarditis?</h2>
<ul>
<li>Aminoglycoside sparing regimens for <em>E. faecalis</em> endocarditis: Ceftriaxone + ampicillin
<ul>
<li><em>E. faecalis</em> has 5 PBPs</li>
<li>At high doses, ampicillin will bind PBP 1,4,5 and ceftriaxone will bind PBPs 2,3</li>
<li>Binding all 5 PBP creates potent synergy</li>
<li>Need to use 2 gram IV q12h of ceftriaxone</li>
</ul></li>
</ul>
<p><a href="images/Screenshot%202024-10-29%20at%2017.17.34.png" class="lightbox" data-gallery="quarto-lightbox-gallery-12"><img data-src="images/Screenshot%202024-10-29%20at%2017.17.34.png" width="800"></a></p>

<aside><div>
<p><span class="citation" data-cites="fernandez-hidalgo.etal_2013">(<a href="#/references" role="doc-biblioref" onclick="">Fernández-Hidalgo et al., 2013</a>)</span></p>
</div></aside></section>
<section id="β-lactamases-ambler-classification" class="slide level2 smaller">
<h2>β-lactamases: Ambler classification</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/Ambler.png" class="lightbox" data-gallery="quarto-lightbox-gallery-13"><img data-src="images/Ambler.png" class="quarto-figure quarto-figure-center" width="800"></a></p>
</figure>
</div>
</section>
<section id="esbl-resistance" class="slide level2">
<h2>ESBL resistance</h2>
<iframe width="1200" height="900" src="https://resistancemap.onehealthtrust.org/AntibioticResistance.php" title="Resistance Map">
</iframe>
</section>
<section id="ceftazidime-avibactam" class="slide level2">
<h2>Ceftazidime-avibactam</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/carbapenemase_spectrum.png" class="lightbox" data-gallery="quarto-lightbox-gallery-14"><img data-src="images/carbapenemase_spectrum.png" class="quarto-figure quarto-figure-center"></a></p>
</figure>
</div>

<aside><div>
<p><span class="citation" data-cites="tamma.hsu_2019">(<a href="#/references" role="doc-biblioref" onclick="">Tamma and Hsu, 2019</a>)</span> <br> Green, susceptibility anticipated to be &gt;80%; yellow, susceptibility anticipated to be 30% to 80%; red, intrinsic resistance or susceptibility anticipated to be &lt;30%.</p>
</div></aside></section>
<section id="th-5th-and-6th-generation-cephalosporins" class="slide level2" data-fig-align="center">
<h2>4th, 5th and 6th generation cephalosporins</h2>
<p><br></p>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/5th%20and6th.png" class="lightbox" data-gallery="quarto-lightbox-gallery-15"><img data-src="images/5th%20and6th.png" class="quarto-figure quarto-figure-center" width="600"></a></p>
</figure>
</div>
</section>
<section id="spectrum-of-activity-1" class="slide level2">
<h2>Spectrum of activity</h2>
<p><br></p>
<h3 class="smaller" id="th-generation-cefepime">4th Generation (Cefepime)</h3>
<p><strong>Key feature: Enhanced stability against AmpC β-lactamases</strong></p>
<p><strong>Gram-Positive Coverage:</strong></p>
<ul>
<li><p>Better than 3rd generation, similar to 2nd generation</p></li>
<li><p>Good activity against <strong>Streptococcus pneumoniae</strong> and viridans streptococci</p></li>
<li><p>Moderate activity against <strong>methicillin-susceptible S. aureus</strong> (MSSA)</p></li>
<li><p>No MRSA or Enterococcus coverage</p></li>
</ul>
<p><strong>Gram-Negative Coverage:</strong></p>
<ul>
<li><p>Excellent <strong>Enterobacteriaceae</strong> coverage, including AmpC producers:</p>
<ul>
<li><p>Enterobacter species</p></li>
<li><p>Citrobacter freundii</p></li>
<li><p>Serratia marcescens</p></li>
<li><p>Providencia species</p></li>
<li><p>Morganella morganii</p></li>
</ul></li>
<li><p><strong>Pseudomonas aeruginosa</strong> coverage comparable to ceftazidime</p></li>
<li><p>Maintains activity against organisms resistant to 3rd generation cephalosporins</p></li>
</ul>
</section>
<section id="cefiderocol" class="slide level2">
<h2>Cefiderocol</h2>
<p><br></p>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/cefiderocol.png" class="lightbox" data-gallery="quarto-lightbox-gallery-16"><img data-src="images/cefiderocol.png" class="quarto-figure quarto-figure-center" width="600"></a></p>
</figure>
</div>

<aside><div>
<p>Image: <a href="https://www.fetroja.com/overcoming-carbapenem-resistance" class="uri">https://www.fetroja.com/overcoming-carbapenem-resistance</a></p>
</div></aside></section>
<section id="cefiderocol-how-does-it-overcome-resistance" class="slide level2">
<h2>Cefiderocol ( ): <br> How does it overcome resistance?</h2>
<p><br></p>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/cefiderocol2.png" class="lightbox" data-gallery="quarto-lightbox-gallery-17"><img data-src="images/cefiderocol2.png" class="quarto-figure quarto-figure-center" width="600"></a></p>
</figure>
</div>

<aside><div>
<p>Image: <a href="https://www.fetroja.com/overcoming-carbapenem-resistance" class="uri">https://www.fetroja.com/overcoming-carbapenem-resistance</a></p>
</div></aside></section>
<section id="pharmacokinetics-of-4-to-6th-generation-cephalosporins" class="slide level2" style=".smaller">
<h2>Pharmacokinetics of 4 to 6th generation cephalosporins</h2>
<p><br></p>
<table class="caption-top" style="width:99%;">
<colgroup>
<col style="width: 15%">
<col style="width: 75%">
<col style="width: 8%">
</colgroup>
<tbody>
<tr class="odd">
<td><strong>Absorption</strong></td>
<td>All intravenous formulations</td>
<td></td>
</tr>
<tr class="even">
<td><strong>Distribution</strong></td>
<td><ul>
<li>0.19-0.3 L/kg</li>
<li>protein binding 20-40%</li>
<li>CSF penetration 20-40% (therapeutic)</li>
</ul></td>
<td></td>
</tr>
<tr class="odd">
<td><strong>Metabolism</strong></td>
<td><ul>
<li><p>No metabolism, renally eliminated</p></li>
<li><p>t½: cefepime (2hr); ceftaroline (2-3 hr); cefiderocol (3hr); ceftolozane-tazobactam (3.1 hr)</p></li>
</ul></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Elimination</strong></td>
<td>All renal</td>
<td></td>
</tr>
<tr class="odd">
<td><strong>PK:PD target</strong></td>
<td>≥ 40-50% <em>f</em>Time<sub>&gt;MIC</sub></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Typical doses</strong></td>
<td><ul>
<li><p>Cefepime 1-2 gram IV q8h or 15 mg/kg IV push, then 6 grams IV over 24 hours;</p></li>
<li><p>Ceftaroline 600 mg IV q8-12h;</p></li>
<li><p>Cefiderocol 2 grams IV q8h over 3 hours;</p></li>
<li><p>Ceftolozane-tazobactam 3 grams over 3 hours q8 hours</p></li>
</ul></td>
<td></td>
</tr>
</tbody>
</table>
</section>
<section id="and-5th-generation-cephalosporin-resistance-in-gram-negatives" class="slide level2">
<h2>4 and 5th generation cephalosporin resistance in Gram negatives</h2>
<p><br></p>
<p><strong>In addition to porin channel alterations, efflux pumps…</strong></p>
<ul>
<li><p><strong>Cefepime:</strong> MBLs and serine beta-lactamases (ESBLs); PBP3 insertions; OXA-48 enzymes</p></li>
<li><p><strong>Ceftazidime-avibactam:</strong> β-Lactamase mutations and overexpression (e.g.,KPC-3 D179Y, T243M, and V240G); penicillin binding protein (PBP) alterations, efflux pump overexpression, porin mutations and deficiencies, AmpC β-Lactamase alterations</p></li>
<li><p><strong>Cefiderocol:</strong> Siderophone uptake/receptor mutations (pirA and cirA), PBP3 Mutations, NDM, KPC and AMPC mutations</p></li>
<li><p><strong>Ceftolozane-tazobactam:</strong> MBLs, ESBLs (CTX-M-15; CMY-10); OXA -type β-Lactamases (OXA-10, OXA-14), OXA-794, OXA 795), PBP alterations</p></li>
</ul>
</section>
<section id="pbp3-insertions" class="slide level2">
<h2>PBP3 insertions</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/pbp.png" class="lightbox" data-gallery="quarto-lightbox-gallery-18"><img data-src="images/pbp.png" class="quarto-figure quarto-figure-center" width="600"></a></p>
</figure>
</div>
<p><span class="citation" data-cites="sethuvel2023">(<a href="#/references" role="doc-biblioref" onclick="">Sethuvel et al., 2023</a>)</span></p>
</section>
<section id="carbapenems" class="slide level2">
<h2>Carbapenems</h2>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><a href="images/carbapenems.png" class="lightbox" data-gallery="quarto-lightbox-gallery-19"><img data-src="images/carbapenems.png" class="quarto-figure quarto-figure-center" width="600"></a></p>
</figure>
</div>
</section>
<<<<<<< HEAD
<section id="spectrum-of-activity-2" class="slide level2">
<h2>Spectrum of activity</h2>
=======
<section id="spectrum-of-activity-2" class="slide level2 smaller">
<h2>Spectrum of activity</h2>
<p>• <strong>Broad gram-positive coverage</strong>: Active against most gram-positive bacteria including methicillin-sensitive <em>Staphylococcus aureus</em> (MSSA), Streptococcus species (including penicillin-resistant <em>S. pneumoniae</em>), and <em>Enterococcus faecalis.</em> However, they lack activity against methicillin-resistant Staphylococcus aureus (MRSA) and Enterococcus faecium.</p>
<p>• <strong>Excellent gram-negative coverage</strong>: Highly effective against Enterobacterales (<em>E. coli, Klebsiella, Proteus, Serratia, Citrobacter, Enterobacte</em>r) including many ESBL and AmpC-producing strains, making them crucial for treating multidrug-resistant gram-negative infections.</p>
<p>• <strong><em>Pseudomonas aeruginosa</em></strong> <strong>activity</strong>: Most carbapenems (except ertapenem) have anti-pseudomonal activity, though resistance is increasingly common. Doripenem and meropenem generally have better anti-pseudomonal activity than imipenem.</p>
<p>• <strong>Anaerobic coverage</strong>: Excellent activity against both gram-positive and gram-negative anaerobes including <em>Bacteroides fragilis</em> group, Clostridium species (except <em>C. difficile</em>), <em>Fusobacterium</em>, and <em>Peptostreptococcus</em>, making them suitable for polymicrobial infections.</p>
<p>• <strong>Atypical pathogen gaps</strong>: Limited or no activity against atypical pathogens including <em>Mycoplasma, Chlamydia, Legionell</em>a, and mycobacteria, requiring alternative agents for these infections.</p>
<p>• <strong>Intrinsic resistance patterns</strong>: Naturally inactive against <em>Stenotrophomonas maltophilia, Burkholderia cepacia</em> complex, and most <em>Acinetobacter</em> species (though imipenem may retain some <em>Acinetobacter</em> activity).</p>
<p>• <strong>Unique spectrum considerations</strong>: Ertapenem lacks anti-pseudomonal and anti-<em>Acinetobacter</em> activity but has a longer half-life allowing once-daily dosing, while newer combinations like meropenem-vaborbactam and imipenem-relebactam restore activity against some KPC-producing Enterobacterales.</p>
</section>
<section id="what-is-not-covered" class="slide level2">
<h2>What is not covered?</h2>
</section>
<section id="gram-positive-gaps" class="slide level2">
<h2>Gram-Positive Gaps</h2>
<ul>
<li><p><strong>MRSA (Methicillin-resistant Staphylococcus aureus)</strong> - One of the most important gaps; requires vancomycin, daptomycin, linezolid, or other anti-MRSA agents</p></li>
<li><p><strong>Enterococcus faecium</strong> - Intrinsically resistant; particularly problematic as VRE (vancomycin-resistant enterococci)</p></li>
<li><p><strong>Coagulase-negative staphylococci (methicillin-resistant)</strong> - Common cause of device-related and catheter infections</p></li>
</ul>
</section>
<section id="gram-negative-gaps" class="slide level2 smaller">
<h2>Gram-Negative Gaps</h2>
<ul>
<li><p><strong>Stenotrophomonas maltophilia</strong> - Intrinsically resistant due to L1 metallo-β-lactamase; requires trimethoprim-sulfamethoxazole or alternatives</p></li>
<li><p><strong>Burkholderia cepacia complex</strong> - Intrinsically resistant; important in cystic fibrosis patients</p></li>
<li><p><strong>Carbapenem-resistant Enterobacterales (CRE)</strong> - Including KPC, NDM, OXA-48 producers; increasingly common worldwide</p></li>
<li><p><strong>Carbapenem-resistant Acinetobacter baumannii</strong> - Major nosocomial pathogen with high mortality</p></li>
<li><p><strong>Serratia spp. (imipenem)</strong></p></li>
<li><p><strong>Elizabethkingia</strong> (formerly Chryseobacterium) <strong>meningosepticum</strong> bapenem-Resistant Organisms <strong>“Stay Alert Elizabeth”</strong></p></li>
<li><p><strong>S</strong> - <strong><em>Stenotrophomonas maltophilia</em></strong> - L1 and L2 β-lactamases; requires TMP-SMX</p></li>
<li><p><strong>A</strong> - <strong><em>Aeromonas species</em></strong> - Some strains produce metallo-β-lactamases (though variable resistance)</p></li>
<li><p><strong>E</strong> - <strong><em>Elizabethkingia meningosepticum</em></strong> - Multiple β-lactamases including metallo-β-lactamases</p></li>
</ul>
</section>
<section id="ertapenem--ape-spectrum-hole" class="slide level2">
<h2>Ertapenem- APE spectrum hole</h2>
</section>
<section id="pharmacokinetics-of-carbapenem-antibiotics" class="slide level2 smaller">
<h2>Pharmacokinetics of Carbapenem Antibiotics</h2>
<table class="caption-top">
<colgroup>
<col style="width: 6%">
<col style="width: 93%">
</colgroup>
<thead>
<tr class="header">
<th>Parameter</th>
<th>Characteristics</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Absorption</strong></td>
<td>All intravenous formulations (ertapenem also IM)</td>
</tr>
<tr class="even">
<td><strong>Distribution</strong></td>
<td>• Vd: 0.15-0.35 L/kg<br>• Protein binding varies widely:<br>&nbsp;&nbsp;- Imipenem: 20%<br>&nbsp;&nbsp;- Meropenem: 2%<br>&nbsp;&nbsp;- Doripenem: 8%<br>&nbsp;&nbsp;- Ertapenem: 85-95%<br>• CSF penetration: 10-30% (inflamed meninges)</td>
</tr>
<tr class="odd">
<td><strong>Metabolism</strong></td>
<td>• Minimal hepatic metabolism<br>• Imipenem requires cilastatin to prevent renal metabolism by DHP-I<br>• t½:<br>&nbsp;&nbsp;- Imipenem: 1 hr<br>&nbsp;&nbsp;- Meropenem: 1 hr<br>&nbsp;&nbsp;- Doripenem: 1 hr<br>&nbsp;&nbsp;- Ertapenem: 4 hr</td>
</tr>
<tr class="even">
<td><strong>Elimination</strong></td>
<td>• Primarily renal (70-95%)<br>• Dose adjustment required for CrCl &lt;50 mL/min<br>• Removed by hemodialysis (except ertapenem)</td>
</tr>
<tr class="odd">
<td><strong>PK/PD Target</strong></td>
<td>≥40% fT&gt;MIC (optimal bactericidal: ≥70% fT&gt;MIC)</td>
</tr>
<tr class="even">
<td><strong>Typical Doses</strong></td>
<td>• <strong>Imipenem-cilastatin</strong>: 500mg-1g IV q6-8h<br>• <strong>Meropenem</strong>: 1-2g IV q8h (3g q8h for meningitis)<br>• <strong>Doripenem</strong>: 500mg IV q8h over 1-4 hours<br>• <strong>Ertapenem</strong>: 1g IV/IM q24h<br>• <strong>Meropenem-vaborbactam</strong>: 4g q8h over 3 hours<br>• <strong>Imipenem-cilastatin-relebactam</strong>: 1.25g q6h</td>
</tr>
</tbody>
</table>
<p><strong>Note</strong>: Extended infusions (3-4 hours) optimize PK/PD target achievement, especially for resistant organisms with elevated MICs.</p>
</section>
<section id="carbapenem-side-effects" class="slide level2">
<h2>Carbapenem side effects</h2>
<ul>
<li><p>Seizures: Impinem &gt; meropenem, ertapenem</p></li>
<li><p>Phlebitis 4%</p></li>
<li><p>Neutropenia</p></li>
<li><p>Eosinophilia</p></li>
<li><p>DRESS</p></li>
<li><p>Diarrhoea 6%</p></li>
<li><p>Deranged LFTs 6%</p></li>
</ul>
>>>>>>> 35cb6bfce63edacb5247c8699c9361b4cafe9ae4
</section>
<section id="references" class="slide level2 smaller scrollable">
<h2>References</h2>

<div id="refs" class="references csl-bib-body" data-entry-spacing="0" role="list">
<div id="ref-antosz.etal_2023a" class="csl-entry" role="listitem">
Antosz K, Battle S, Chang J, Scheetz MH, Al-Hasan M, Bookstaver PB. Cefazolin in the treatment of central nervous system infections: A narrative review and recommendation. Pharmacotherapy 2023;43:85–95. <a href="https://doi.org/10.1002/phar.2750">https://doi.org/10.1002/phar.2750</a>.
</div>
<div id="ref-fernandez-hidalgo.etal_2013" class="csl-entry" role="listitem">
Fernández-Hidalgo N, Almirante B, Gavaldà J, Gurgui M, Peña C, Alarcón A de, et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating enterococcus faecalis infective endocarditis. Clinical Infectious Diseases 2013;56:1261–8. <a href="https://doi.org/10.1093/cid/cit052">https://doi.org/10.1093/cid/cit052</a>.
</div>
<div id="ref-mccreary.etal_2023b" class="csl-entry" role="listitem">
McCreary EK, Johnson MD, Jones TM, Spires SS, Davis AE, Dyer AP, et al. Antibiotic myths for the infectious diseases clinician. Clinical Infectious Diseases 2023;77:1120–5. <a href="https://doi.org/10.1093/cid/ciad357">https://doi.org/10.1093/cid/ciad357</a>.
</div>
<div id="ref-paul.etal_2011" class="csl-entry" role="listitem">
Paul M, Zemer-Wassercug N, Talker O, Lishtzinsky Y, Lev B, Samra Z, et al. Are all beta-lactams similarly effective in the treatment of methicillin-sensitive staphylococcus aureus bacteraemia? Clinical Microbiology and Infection 2011;17:1581–6. <a href="https://doi.org/10.1111/j.1469-0691.2010.03425.x">https://doi.org/10.1111/j.1469-0691.2010.03425.x</a>.
</div>
<div id="ref-sethuvel2023" class="csl-entry" role="listitem">
Sethuvel DPM, Bakthavatchalam YD, Karthik M, Irulappan M, Shrivastava R, Periasamy H, et al. Β-lactam resistance in ESKAPE pathogens mediated through modifications in penicillin-binding proteins: An overview. Infectious Diseases and Therapy 2023;12:829–41. <a href="https://doi.org/10.1007/s40121-023-00771-8">https://doi.org/10.1007/s40121-023-00771-8</a>.
</div>
<div id="ref-tamma.hsu_2019" class="csl-entry" role="listitem">
Tamma PD, Hsu AJ. Defining the role of novel β-lactam agents that target carbapenem-resistant gram-negative organisms. Journal of the Pediatric Infectious Diseases Society 2019;8:251–60. <a href="https://doi.org/10.1093/jpids/piz002">https://doi.org/10.1093/jpids/piz002</a>.
</div>
<div id="ref-zelenitsky.etal_2018" class="csl-entry" role="listitem">
Zelenitsky SA, Beahm NP, Iacovides H, Ariano RE, Zhanel G. Limitations of ceftriaxone compared with cefazolin against MSSA: An integrated pharmacodynamic analysis. The Journal of Antimicrobial Chemotherapy 2018;73:1888–94. <a href="https://doi.org/10.1093/jac/dky120">https://doi.org/10.1093/jac/dky120</a>.
</div>
</div>
</section>
    </div>
  <div class="quarto-auto-generated-content" style="display: none;">
<div class="footer footer-default">

</div>
</div></div>

  <script>window.backupDefine = window.define; window.define = undefined;</script>
  <script src="Lecture1_files/libs/revealjs/dist/reveal.js"></script>
  <!-- reveal.js plugins -->
  <script src="Lecture1_files/libs/revealjs/plugin/quarto-line-highlight/line-highlight.js"></script>
  <script src="Lecture1_files/libs/revealjs/plugin/pdf-export/pdfexport.js"></script>
  <script src="Lecture1_files/libs/revealjs/plugin/reveal-menu/menu.js"></script>
  <script src="Lecture1_files/libs/revealjs/plugin/reveal-menu/quarto-menu.js"></script>
  <script src="Lecture1_files/libs/revealjs/plugin/reveal-chalkboard/plugin.js"></script>
  <script src="Lecture1_files/libs/revealjs/plugin/quarto-support/support.js"></script>
  

  <script src="Lecture1_files/libs/revealjs/plugin/notes/notes.js"></script>
  <script src="Lecture1_files/libs/revealjs/plugin/search/search.js"></script>
  <script src="Lecture1_files/libs/revealjs/plugin/zoom/zoom.js"></script>
  <script src="Lecture1_files/libs/revealjs/plugin/math/math.js"></script>
  <script>window.define = window.backupDefine; window.backupDefine = undefined;</script>

  <script>

      // Full list of configuration options available at:
      // https://revealjs.com/config/
      Reveal.initialize({
'controlsAuto': false,
'previewLinksAuto': false,
'pdfSeparateFragments': false,
'autoAnimateEasing': "ease",
'autoAnimateDuration': 1,
'autoAnimateUnmatched': true,
'jumpToSlide': true,
'menu': {"side":"left","useTextContentForMissingTitles":true,"markers":false,"loadIcons":false,"custom":[{"title":"Tools","icon":"<i class=\"fas fa-gear\"></i>","content":"<ul class=\"slide-menu-items\">\n<li class=\"slide-tool-item active\" data-item=\"0\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.fullscreen(event)\"><kbd>f</kbd> Fullscreen</a></li>\n<li class=\"slide-tool-item\" data-item=\"1\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.speakerMode(event)\"><kbd>s</kbd> Speaker View</a></li>\n<li class=\"slide-tool-item\" data-item=\"2\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.overview(event)\"><kbd>o</kbd> Slide Overview</a></li>\n<li class=\"slide-tool-item\" data-item=\"3\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.togglePdfExport(event)\"><kbd>e</kbd> PDF Export Mode</a></li>\n<li class=\"slide-tool-item\" data-item=\"4\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.toggleScrollView(event)\"><kbd>r</kbd> Scroll View Mode</a></li>\n<li class=\"slide-tool-item\" data-item=\"5\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.toggleChalkboard(event)\"><kbd>b</kbd> Toggle Chalkboard</a></li>\n<li class=\"slide-tool-item\" data-item=\"6\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.toggleNotesCanvas(event)\"><kbd>c</kbd> Toggle Notes Canvas</a></li>\n<li class=\"slide-tool-item\" data-item=\"7\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.downloadDrawings(event)\"><kbd>d</kbd> Download Drawings</a></li>\n<li class=\"slide-tool-item\" data-item=\"8\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.keyboardHelp(event)\"><kbd>?</kbd> Keyboard Help</a></li>\n</ul>"}],"openButton":true},
'chalkboard': {"buttons":true},
'smaller': false,
 
        // Display controls in the bottom right corner
        controls: true,

        // Help the user learn the controls by providing hints, for example by
        // bouncing the down arrow when they first encounter a vertical slide
        controlsTutorial: false,

        // Determines where controls appear, "edges" or "bottom-right"
        controlsLayout: 'edges',

        // Visibility rule for backwards navigation arrows; "faded", "hidden"
        // or "visible"
        controlsBackArrows: 'faded',

        // Display a presentation progress bar
        progress: true,

        // Display the page number of the current slide
        slideNumber: 'c/t',

        // 'all', 'print', or 'speaker'
        showSlideNumber: 'all',

        // Add the current slide number to the URL hash so that reloading the
        // page/copying the URL will return you to the same slide
        hash: true,

        // Start with 1 for the hash rather than 0
        hashOneBasedIndex: false,

        // Flags if we should monitor the hash and change slides accordingly
        respondToHashChanges: true,

        // Push each slide change to the browser history
        history: true,

        // Enable keyboard shortcuts for navigation
        keyboard: true,

        // Enable the slide overview mode
        overview: true,

        // Disables the default reveal.js slide layout (scaling and centering)
        // so that you can use custom CSS layout
        disableLayout: false,

        // Vertical centering of slides
        center: false,

        // Enables touch navigation on devices with touch input
        touch: true,

        // Loop the presentation
        loop: false,

        // Change the presentation direction to be RTL
        rtl: false,

        // see https://revealjs.com/vertical-slides/#navigation-mode
        navigationMode: 'linear',

        // Randomizes the order of slides each time the presentation loads
        shuffle: false,

        // Turns fragments on and off globally
        fragments: true,

        // Flags whether to include the current fragment in the URL,
        // so that reloading brings you to the same fragment position
        fragmentInURL: false,

        // Flags if the presentation is running in an embedded mode,
        // i.e. contained within a limited portion of the screen
        embedded: false,

        // Flags if we should show a help overlay when the questionmark
        // key is pressed
        help: true,

        // Flags if it should be possible to pause the presentation (blackout)
        pause: true,

        // Flags if speaker notes should be visible to all viewers
        showNotes: false,

        // Global override for autoplaying embedded media (null/true/false)
        autoPlayMedia: null,

        // Global override for preloading lazy-loaded iframes (null/true/false)
        preloadIframes: null,

        // Number of milliseconds between automatically proceeding to the
        // next slide, disabled when set to 0, this value can be overwritten
        // by using a data-autoslide attribute on your slides
        autoSlide: 0,

        // Stop auto-sliding after user input
        autoSlideStoppable: true,

        // Use this method for navigation when auto-sliding
        autoSlideMethod: null,

        // Specify the average time in seconds that you think you will spend
        // presenting each slide. This is used to show a pacing timer in the
        // speaker view
        defaultTiming: null,

        // Enable slide navigation via mouse wheel
        mouseWheel: false,

        // The display mode that will be used to show slides
        display: 'block',

        // Hide cursor if inactive
        hideInactiveCursor: true,

        // Time before the cursor is hidden (in ms)
        hideCursorTime: 5000,

        // Opens links in an iframe preview overlay
        previewLinks: false,

        // Transition style (none/fade/slide/convex/concave/zoom)
        transition: 'fade',

        // Transition speed (default/fast/slow)
        transitionSpeed: 'fast',

        // Transition style for full page slide backgrounds
        // (none/fade/slide/convex/concave/zoom)
        backgroundTransition: 'none',

        // Number of slides away from the current that are visible
        viewDistance: 3,

        // Number of slides away from the current that are visible on mobile
        // devices. It is advisable to set this to a lower number than
        // viewDistance in order to save resources.
        mobileViewDistance: 2,

        // The "normal" size of the presentation, aspect ratio will be preserved
        // when the presentation is scaled to fit different resolutions. Can be
        // specified using percentage units.
        width: 1050,

        height: 700,

        // Factor of the display size that should remain empty around the content
        margin: 0.1,

        math: {
          mathjax: 'https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.9/MathJax.js',
          config: 'TeX-AMS_HTML-full',
          tex2jax: {
            inlineMath: [['\\(','\\)']],
            displayMath: [['\\[','\\]']],
            balanceBraces: true,
            processEscapes: false,
            processRefs: true,
            processEnvironments: true,
            preview: 'TeX',
            skipTags: ['script','noscript','style','textarea','pre','code'],
            ignoreClass: 'tex2jax_ignore',
            processClass: 'tex2jax_process'
          },
        },

        // reveal.js plugins
        plugins: [QuartoLineHighlight, PdfExport, RevealMenu, RevealChalkboard, QuartoSupport,

          RevealMath,
          RevealNotes,
          RevealSearch,
          RevealZoom
        ]
      });
    </script>
    <script id="quarto-html-after-body" type="application/javascript">
      window.document.addEventListener("DOMContentLoaded", function (event) {
        const tabsets =  window.document.querySelectorAll(".panel-tabset-tabby")
        tabsets.forEach(function(tabset) {
          const tabby = new Tabby('#' + tabset.id);
        });
        const isCodeAnnotation = (el) => {
          for (const clz of el.classList) {
            if (clz.startsWith('code-annotation-')) {                     
              return true;
            }
          }
          return false;
        }
        const onCopySuccess = function(e) {
          // button target
          const button = e.trigger;
          // don't keep focus
          button.blur();
          // flash "checked"
          button.classList.add('code-copy-button-checked');
          var currentTitle = button.getAttribute("title");
          button.setAttribute("title", "Copied!");
          let tooltip;
          if (window.bootstrap) {
            button.setAttribute("data-bs-toggle", "tooltip");
            button.setAttribute("data-bs-placement", "left");
            button.setAttribute("data-bs-title", "Copied!");
            tooltip = new bootstrap.Tooltip(button, 
              { trigger: "manual", 
                customClass: "code-copy-button-tooltip",
                offset: [0, -8]});
            tooltip.show();    
          }
          setTimeout(function() {
            if (tooltip) {
              tooltip.hide();
              button.removeAttribute("data-bs-title");
              button.removeAttribute("data-bs-toggle");
              button.removeAttribute("data-bs-placement");
            }
            button.setAttribute("title", currentTitle);
            button.classList.remove('code-copy-button-checked');
          }, 1000);
          // clear code selection
          e.clearSelection();
        }
        const getTextToCopy = function(trigger) {
            const codeEl = trigger.previousElementSibling.cloneNode(true);
            for (const childEl of codeEl.children) {
              if (isCodeAnnotation(childEl)) {
                childEl.remove();
              }
            }
            return codeEl.innerText;
        }
        const clipboard = new window.ClipboardJS('.code-copy-button:not([data-in-quarto-modal])', {
          text: getTextToCopy
        });
        clipboard.on('success', onCopySuccess);
        if (window.document.getElementById('quarto-embedded-source-code-modal')) {
          const clipboardModal = new window.ClipboardJS('.code-copy-button[data-in-quarto-modal]', {
            text: getTextToCopy,
            container: window.document.getElementById('quarto-embedded-source-code-modal')
          });
          clipboardModal.on('success', onCopySuccess);
        }
          var localhostRegex = new RegExp(/^(?:http|https):\/\/localhost\:?[0-9]*\//);
          var mailtoRegex = new RegExp(/^mailto:/);
            var filterRegex = new RegExp('/' + window.location.host + '/');
          var isInternal = (href) => {
              return filterRegex.test(href) || localhostRegex.test(href) || mailtoRegex.test(href);
          }
          // Inspect non-navigation links and adorn them if external
         var links = window.document.querySelectorAll('a[href]:not(.nav-link):not(.navbar-brand):not(.toc-action):not(.sidebar-link):not(.sidebar-item-toggle):not(.pagination-link):not(.no-external):not([aria-hidden]):not(.dropdown-item):not(.quarto-navigation-tool):not(.about-link)');
          for (var i=0; i<links.length; i++) {
            const link = links[i];
            if (!isInternal(link.href)) {
              // undo the damage that might have been done by quarto-nav.js in the case of
              // links that we want to consider external
              if (link.dataset.originalHref !== undefined) {
                link.href = link.dataset.originalHref;
              }
            }
          }
        function tippyHover(el, contentFn, onTriggerFn, onUntriggerFn) {
          const config = {
            allowHTML: true,
            maxWidth: 500,
            delay: 100,
            arrow: false,
            appendTo: function(el) {
                return el.closest('section.slide') || el.parentElement;
            },
            interactive: true,
            interactiveBorder: 10,
            theme: 'light-border',
            placement: 'bottom-start',
          };
          if (contentFn) {
            config.content = contentFn;
          }
          if (onTriggerFn) {
            config.onTrigger = onTriggerFn;
          }
          if (onUntriggerFn) {
            config.onUntrigger = onUntriggerFn;
          }
            config['offset'] = [0,0];
            config['maxWidth'] = 700;
          window.tippy(el, config); 
        }
        const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
        for (var i=0; i<noterefs.length; i++) {
          const ref = noterefs[i];
          tippyHover(ref, function() {
            // use id or data attribute instead here
            let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
            try { href = new URL(href).hash; } catch {}
            const id = href.replace(/^#\/?/, "");
            const note = window.document.getElementById(id);
            if (note) {
              return note.innerHTML;
            } else {
              return "";
            }
          });
        }
        const findCites = (el) => {
          const parentEl = el.parentElement;
          if (parentEl) {
            const cites = parentEl.dataset.cites;
            if (cites) {
              return {
                el,
                cites: cites.split(' ')
              };
            } else {
              return findCites(el.parentElement)
            }
          } else {
            return undefined;
          }
        };
        var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
        for (var i=0; i<bibliorefs.length; i++) {
          const ref = bibliorefs[i];
          const citeInfo = findCites(ref);
          if (citeInfo) {
            tippyHover(citeInfo.el, function() {
              var popup = window.document.createElement('div');
              citeInfo.cites.forEach(function(cite) {
                var citeDiv = window.document.createElement('div');
                citeDiv.classList.add('hanging-indent');
                citeDiv.classList.add('csl-entry');
                var biblioDiv = window.document.getElementById('ref-' + cite);
                if (biblioDiv) {
                  citeDiv.innerHTML = biblioDiv.innerHTML;
                }
                popup.appendChild(citeDiv);
              });
              return popup.innerHTML;
            });
          }
        }
      });
      </script>
    <script>var lightboxQuarto = GLightbox({"closeEffect":"zoom","descPosition":"bottom","loop":false,"openEffect":"zoom","selector":".lightbox"});
    (function() {
      let previousOnload = window.onload;
      window.onload = () => {
        if (previousOnload) {
          previousOnload();
        }
        lightboxQuarto.on('slide_before_load', (data) => {
          const { slideIndex, slideNode, slideConfig, player, trigger } = data;
          const href = trigger.getAttribute('href');
          if (href !== null) {
            const imgEl = window.document.querySelector(`a[href="${href}"] img`);
            if (imgEl !== null) {
              const srcAttr = imgEl.getAttribute("src");
              if (srcAttr && srcAttr.startsWith("data:")) {
                slideConfig.href = srcAttr;
              }
            }
          } 
        });
      
        lightboxQuarto.on('slide_after_load', (data) => {
          const { slideIndex, slideNode, slideConfig, player, trigger } = data;
          if (window.Quarto?.typesetMath) {
            window.Quarto.typesetMath(slideNode);
          }
        });
      
      };
      
    })();
              </script>
    

</body></html>